407 related articles for article (PubMed ID: 10357155)
1. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
Haas S; Walenga JM; Jeske WP; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 1():67-75. PubMed ID: 10357155
[TBL] [Abstract][Full Text] [Related]
2. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
3. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.
Herbert JM; Savi P; Jeske WP; Walenga JM
Thromb Haemost; 1998 Aug; 80(2):326-31. PubMed ID: 9716161
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
Mak KH; Kottke-Marchant K; Brooks LM; Topol EJ
Thromb Haemost; 1998 Dec; 80(6):989-93. PubMed ID: 9869172
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
6. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia.
Walenga JM; Jeske WP; Fasanella AR; Wood JJ; Bakhos M
Semin Thromb Hemost; 1999; 25 Suppl 1():43-9. PubMed ID: 10357151
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.
Jeske WP; Walenga JM; Szatkowski E; Ero M; Herbert JM; Haas S; Bakhos M
Thromb Res; 1997 Nov; 88(3):271-81. PubMed ID: 9526947
[TBL] [Abstract][Full Text] [Related]
8. Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin.
Selleng K; Selleng S; Raschke R; Schmidt CO; Rosenblood GS; Greinacher A; Warkentin TE
Am J Hematol; 2005 Mar; 78(3):188-92. PubMed ID: 15726594
[TBL] [Abstract][Full Text] [Related]
9. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation.
Bream-Rouwenhorst HR; Hobbs RA; Horwitz PA
J Interv Cardiol; 2008 Aug; 21(4):350-6. PubMed ID: 18537872
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
12. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia.
Gobbi G; Mirandola P; Tazzari PL; Talarico E; Caimi L; Martini G; Papa S; Conte R; Manzoli FA; Vitale M
Cytometry B Clin Cytom; 2004 Mar; 58(1):32-8. PubMed ID: 14994373
[TBL] [Abstract][Full Text] [Related]
13. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
14. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
15. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
16. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
17. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
[TBL] [Abstract][Full Text] [Related]
18. Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.
Prechel MM; Jeske WP; Walenga JM
Thromb Res; 2010 Apr; 125(4):e143-8. PubMed ID: 19931120
[TBL] [Abstract][Full Text] [Related]
19. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost.
Antoniou T; Kapetanakis EI; Theodoraki K; Rellia P; Thanopoulos A; Kotiou M; Zarkalis D; Alivizatos P
Heart Surg Forum; 2002; 5(4):354-7. PubMed ID: 12538117
[TBL] [Abstract][Full Text] [Related]
20. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients.
Polgár J; Eichler P; Greinacher A; Clemetson KJ
Blood; 1998 Jan; 91(2):549-54. PubMed ID: 9427708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
